Saturday 17 October 2026
Export BIOA’s income statement to Excel — free account
BioAge Labs, Inc.
BIOA Healthcare Drug Manufacturers Specialty & Generic
BioAge Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million. In the quarter to June 2026, revenue grew 1.62%, EPS grew 3.33%, free cash flow grew 2.68% and total debt fell 83.6%, each against the same quarter a year earlier.
4.82
0.53
−9.91%
Follow BIOA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.41 |
+8 more quarters Free account |
P/S ratio |
106.13 | 72.02 | 52.85 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(57.06) | (30.90) | (16.83) | (13.14) | |
P/B ratio |
2.93 | 1.96 | 1.75 | 0.76 | |
Price to Tangible BV |
2.93 | 1.96 | 1.75 | 0.76 | |
EV/Sales |
75.56 | 35.09 | 22.01 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.78 | |
EV/Operating CF |
(8.93) | (4.10) | (2.43) | 1.19 | |
EV/FCF |
(3.22) | (1.49) | (0.84) | 1.18 | |
Quick Ratio |
16.62 | 24.26 | 14.00 | 11.69 | |
Current Ratio |
17.19 | 24.76 | 14.24 | 11.87 | |
Net Debt/EBITDA |
10.89 | 15.09 | 9.82 | 12.20 | |
Debt/Assets |
0.00% | 0.29% | 0.90% | 1.35% | |
Debt/Equity |
0.00 | 0.00 | 0.01 | 0.01 | |
Asset Turnover |
0.03 | 0.03 | 0.03 | 0.00 | |
Operating CF/Net income |
0.74 | 1.08 | 1.09 | 0.80 | |
Capex/Depreciation |
(4.69) | (0.41) | (2,244.33) | (0.45) | |
Interest Coverage |
(29,333.00) | (650.64) | (308.95) | (155.30) | |
Research and Development Expense of Revenue |
994.08% | 736.29% | 795.97% | 901.31% | |
Selling, General and Administrative Expense of Revenue |
302.69% | 279.11% | 227.45% | 325.27% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
174.17% | 153.54% | 88.43% | 135.88% | |
Graham Net Nets |
0.28 | 0.50 | 0.56 | 1.25 | |
Graham Number |
0.00 | 0.00 | 0.00 | 49.81 | |
Earnings Yield |
(9.71%) | (13.72%) | (16.93%) | 242.33% | |
Free Cash Flow Yield |
(22.10%) | (32.76%) | (49.87%) | (28.06%) | |
Revenue per Share |
0.05 | 0.07 | 0.09 | 0.06 | |
Operating CF per Share |
(0.43) | (0.57) | (0.79) | (0.45) | |
Capex per Share |
(0.01) | 0.00 | (4.31) | 0.00 | |
Free Cash Flow per Share |
(0.44) | (0.57) | (5.10) | (0.45) | |
Cash per Share |
7.11 | 9.02 | 7.82 | 7.97 | |
Shareholders Equity per Share |
8.36 | 8.92 | 7.57 | 7.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.36 | 8.92 | 7.57 | 7.74 | |
Free Cash Flow |
(19.59) | (24.07) | (183.11) | (16.07) | |
Working Capital |
311.10 | 376.03 | 266.66 | 266.34 | |
Capital Expenditures |
(0.33) | (0.03) | (154.86) | (0.02) | |
Net Current Asset Value |
308.30 | 373.33 | 263.96 | 263.20 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.78 | |
Capex to Sales |
0.13 | 0.01 | 50.31 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.61 | 0.54 | — | — | |
Average Payables |
3.49 | 3.53 | 2.34 | 3.56 | |
Average Assets |
359.54 | 370.75 | 326.56 | 321.24 | |
Average Common Equity |
334.85 | 346.14 | 297.59 | 295.61 |
Columns are period end dates